New combo therapy shows promise for Hard-to-Treat lung cancer
NCT ID NCT03527108
First seen Jan 20, 2026 · Last updated May 23, 2026 · Updated 14 times
Summary
This study tests a combination of two drugs, nivolumab and ramucirumab, in people with advanced non-small cell lung cancer that has returned or spread. Participants must have already received immunotherapy. The main goal is to see if the combination can control the disease, meaning it stops or shrinks the cancer for a period of time.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Fox Chase Cancer Center
Philadelphia, Pennsylvania, 19111, United States
-
NYU Langone
New York, New York, 10016, United States
Conditions
Explore the condition pages connected to this study.